Catalyst Wire Dossier Catalyst Wire Dossier

NEOPROFEN

IBUPROFEN LYSINE · Recordati Rare Diseases Inc.
Drug timelines are a Plus or Pro feature.

9 regulatory and trial events tracked for NEOPROFEN, covering 2008-09-12 to 2023-10-25. Get the full timeline:

Most recent: FDA Approved: NEOPROFEN — Supplemental Application (Recordati Rare Diseases Inc.)

See pricing